Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Subscribe

Logo for

Science 319 (5870): 1676-1679

Copyright © 2008 by the American Association for the Advancement of Science

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

Georg Lenz,1* R. Eric Davis,1* Vu N. Ngo,1 Lloyd Lam,1 Thaddeus C. George,2 George W. Wright,3 Sandeep S. Dave,1 Hong Zhao,1 Weihong Xu,1 Andreas Rosenwald,4 German Ott,4,5 Hans Konrad Muller-Hermelink,4 Randy D. Gascoyne,6 Joseph M. Connors,6 Lisa M. Rimsza,7 Elias Campo,8 Elaine S. Jaffe,9 Jan Delabie,10 Erlend B. Smeland,11,12 Richard I. Fisher,13,14 Wing C. Chan,15 Louis M. Staudt1{dagger}

Abstract: Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. In the least curable (ABC) subtype of DLBCL, survival of the malignant cells is dependent on constitutive activation of the nuclear factor–{kappa}B (NF-{kappa}B) signaling pathway. In normal B cells, antigen receptor–induced NF-{kappa}B activation requires CARD11, a cytoplasmic scaffolding protein. To determine whether CARD11 contributes to tumorigenesis, we sequenced the CARD11 gene in human DLBCL tumors. We detected missense mutations in 7 of 73 ABC DLBCL biopsies (9.6%), all within exons encoding the coiled-coil domain. Experimental introduction of CARD11 coiled-coil domain mutants into lymphoma cell lines resulted in constitutive NF-{kappa}B activation and enhanced NF-{kappa}B activity upon antigen receptor stimulation. These results demonstrate that CARD11 is a bona fide oncogenein DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway for DLBCL therapy.

1 Metabolism Branch, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
2 Amnis Corporation, Seattle, WA 98121, USA.
3 Biometric Research Branch, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
4 Department of Pathology, University of Würzburg, 97080 Würzburg, Germany.
5 Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany.
6 British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada.
7 Department of Pathology, University of Arizona, Tucson, AZ 85724, USA.
8 Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
9 Laboratory of Pathology, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
10 Department of Immunology, Rikshospitalet-Radiumhospitalet Medical Center, N-0310 Oslo, Norway.
11 Institute for Cancer Research, Rikshospitalet University Hospital, N-0310 Oslo, Norway.
12 Centre for Cancer Biomedicine, Faculty Division, Norwegian Radium Hospital, University of Oslo, N-0310 Oslo, Norway.
13 Southwest Oncology Group, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106, USA.
14 James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA.
15 Departments of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

* These authors contributed equally to this work.

{dagger} To whom correspondence should be addressed. E-mail: lstaudt{at}mail.nih.gov

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Leveraging Cancer Genome Information in Hematologic Malignancies.
R. Rampal and R. L. Levine (2013)
J. Clin. Oncol. 31, 1885-1892
   Abstract »    Full Text »    PDF »
Kinase-Independent Feedback of the TAK1/TAB1 Complex on BCL10 Turnover and NF-{kappa}B Activation.
M. E. Moreno-Garcia, K. Sommer, H. Rincon-Arano, M. Brault, J. Ninomiya-Tsuji, L. E. Matesic, and D. J. Rawlings (2013)
Mol. Cell. Biol. 33, 1149-1163
   Abstract »    Full Text »    PDF »
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
K. Dunleavy, C. Grant, and W. H. Wilson (2013)
Therapeutic Advances in Hematology 4, 43-57
   Abstract »    PDF »
Genetic heterogeneity of diffuse large B-cell lymphoma.
J. Zhang, V. Grubor, C. L. Love, A. Banerjee, K. L. Richards, P. A. Mieczkowski, C. Dunphy, W. Choi, W. Y. Au, G. Srivastava, et al. (2013)
PNAS 110, 1398-1403
   Abstract »    Full Text »    PDF »
A Quantitative Signaling Screen Identifies CARD11 Mutations in the CARD and LATCH Domains That Induce Bcl10 Ubiquitination and Human Lymphoma Cell Survival.
W. Chan, T. B. Schaffer, and J. L. Pomerantz (2013)
Mol. Cell. Biol. 33, 429-443
   Abstract »    Full Text »    PDF »
I{kappa}B Kinase {varepsilon} Phosphorylates TRAF2 To Promote Mammary Epithelial Cell Transformation.
R. R. Shen, A. Y. Zhou, E. Kim, E. Lim, H. Habelhah, and W. C. Hahn (2012)
Mol. Cell. Biol. 32, 4756-4768
   Abstract »    Full Text »    PDF »
Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.
A. L. Snow, W. Xiao, J. R. Stinson, W. Lu, B. Chaigne-Delalande, L. Zheng, S. Pittaluga, H. F. Matthews, R. Schmitz, S. Jhavar, et al. (2012)
J. Exp. Med. 209, 2247-2261
   Abstract »    Full Text »    PDF »
Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival.
S. M. Ranuncolo, S. Pittaluga, M. O. Evbuomwan, E. S. Jaffe, and B. A. Lewis (2012)
Blood 120, 3756-3763
   Abstract »    Full Text »    PDF »
Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production.
Y. S. Jeelall, J. Q. Wang, H.-D. Law, H. Domaschenz, H. K. H. Fung, A. Kallies, S. L. Nutt, C. C. Goodnow, and K. Horikawa (2012)
J. Exp. Med. 209, 1907-1917
   Abstract »    Full Text »    PDF »
The evolving contribution of hematopoietic progenitor cells to lymphomagenesis.
O. Weigert and D. M. Weinstock (2012)
Blood 120, 2553-2561
   Abstract »    Full Text »    PDF »
Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions.
J. J. Steinhardt and R. B. Gartenhaus (2012)
Clin. Cancer Res. 18, 4538-4548
   Abstract »    Full Text »    PDF »
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.
D. Rossi, V. Trifonov, M. Fangazio, A. Bruscaggin, S. Rasi, V. Spina, S. Monti, T. Vaisitti, F. Arruga, R. Fama, et al. (2012)
J. Exp. Med. 209, 1537-1551
   Abstract »    Full Text »    PDF »
Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.
M. Pulvino, Y. Liang, D. Oleksyn, M. DeRan, E. Van Pelt, J. Shapiro, I. Sanz, L. Chen, and J. Zhao (2012)
Blood 120, 1668-1677
   Abstract »    Full Text »    PDF »
Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
D. Merino, S. L. Khaw, S. P. Glaser, D. J. Anderson, L. D. Belmont, C. Wong, P. Yue, M. Robati, B. Phipson, W. D. Fairlie, et al. (2012)
Blood 119, 5807-5816
   Abstract »    Full Text »    PDF »
MicroRNAs miR-125a and miR-125b constitutively activate the NF-{kappa}B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20).
S.-W. Kim, K. Ramasamy, H. Bouamar, A.-P. Lin, D. Jiang, and R. C. T. Aguiar (2012)
PNAS 109, 7865-7870
   Abstract »    Full Text »    PDF »
Neuroepithelial Transforming Gene 1 (Net1) Binds to Caspase Activation and Recruitment Domain (CARD)- and Membrane-associated Guanylate Kinase-like Domain-containing (CARMA) Proteins and Regulates Nuclear Factor {kappa}B Activation.
M. Vessichelli, A. Ferravante, T. Zotti, C. Reale, I. Scudiero, G. Picariello, P. Vito, and R. Stilo (2012)
J. Biol. Chem. 287, 13722-13730
   Abstract »    Full Text »    PDF »
How I treat HIV-associated lymphoma.
K. Dunleavy and W. H. Wilson (2012)
Blood 119, 3245-3255
   Abstract »    Full Text »    PDF »
BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.
Q. Yan, Y. Huang, A. J. Watkins, S. Kocialkowski, N. Zeng, R. A. Hamoudi, P. G. Isaacson, L. de Leval, A. Wotherspoon, and M.-Q. Du (2012)
Haematologica 97, 595-598
   Abstract »    Full Text »    PDF »
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
J. G. Lohr, P. Stojanov, M. S. Lawrence, D. Auclair, B. Chapuy, C. Sougnez, P. Cruz-Gordillo, B. Knoechel, Y. W. Asmann, S. L. Slager, et al. (2012)
PNAS 109, 3879-3884
   Abstract »    Full Text »    PDF »
Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis.
M. R. Martinez, A. Corradin, U. Klein, M. J. Alvarez, G. M. Toffolo, B. di Camillo, A. Califano, and G. A. Stolovitzky (2012)
PNAS 109, 2672-2677
   Abstract »    Full Text »    PDF »
SYK inhibition and response prediction in diffuse large B-cell lymphoma.
S. Cheng, G. Coffey, X. H. Zhang, R. Shaknovich, Z. Song, P. Lu, A. Pandey, A. M. Melnick, U. Sinha, and Y. L. Wang (2011)
Blood 118, 6342-6352
   Abstract »    Full Text »    PDF »
The molecular biology of diffuse large B-cell lymphoma.
M. Frick, B. Dorken, and G. Lenz (2011)
Therapeutic Advances in Hematology 2, 369-379
   Abstract »    PDF »
Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification.
E. S. Jaffe and S. Pittaluga (2011)
Hematology 2011, 506-514
   Abstract »    Full Text »    PDF »
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study.
C. Thieblemont, J. Briere, N. Mounier, H.-U. Voelker, W. Cuccuini, E. Hirchaud, A. Rosenwald, A. Jack, C. Sundstrom, S. Cogliatti, et al. (2011)
J. Clin. Oncol. 29, 4079-4087
   Abstract »    Full Text »    PDF »
MALT1 Protease: A New Therapeutic Target in B Lymphoma and Beyond?.
L. M. McAllister-Lucas, M. Baens, and P. C. Lucas (2011)
Clin. Cancer Res. 17, 6623-6631
   Abstract »    Full Text »    PDF »
Opposing roles of NF-{kappa}B in anti-cancer treatment outcome unveiled by cross-species investigations.
H. Jing, J. Kase, J. R. Dorr, M. Milanovic, D. Lenze, M. Grau, G. Beuster, S. Ji, M. Reimann, P. Lenz, et al. (2011)
Genes & Dev. 25, 2137-2146
   Abstract »    Full Text »    PDF »
C/EBP{alpha}, C/EBP{alpha} Oncoproteins, or C/EBP{beta} Preferentially Bind NF-{kappa}B p50 Compared with p65, Focusing Therapeutic Targeting on the C/EBP:p50 Interaction.
J. E. Dooher, I. Paz-Priel, S. Houng, A. S. Baldwin Jr, and A. D. Friedman (2011)
Mol. Cancer Res. 9, 1395-1405
   Abstract »    Full Text »    PDF »
Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses.
K. Karube, M. Nakagawa, S. Tsuzuki, I. Takeuchi, K. Honma, Y. Nakashima, N. Shimizu, Y.-H. Ko, Y. Morishima, K. Ohshima, et al. (2011)
Blood 118, 3195-3204
   Abstract »    Full Text »    PDF »
NEMO-Binding Domain Peptide Inhibits Constitutive NF-{kappa}B Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma.
A. Gaurnier-Hausser, R. Patel, A. S. Baldwin, M. J. May, and N. J. Mason (2011)
Clin. Cancer Res. 17, 4661-4671
   Abstract »    Full Text »    PDF »
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.
T. M. Cardesa-Salzmann, L. Colomo, G. Gutierrez, W. C. Chan, D. Weisenburger, F. Climent, E. Gonzalez-Barca, S. Mercadal, L. Arenillas, S. Serrano, et al. (2011)
Haematologica 96, 996-1001
   Abstract »    Full Text »    PDF »
B-cell receptors and heavy chain diseases: guilty by association?.
D. Corcos, M. J. Osborn, and L. S. Matheson (2011)
Blood 117, 6991-6998
   Abstract »    Full Text »    PDF »
MicroRNAs in NF-{kappa}B signaling.
X. Ma, L. E. Becker Buscaglia, J. R. Barker, and Y. Li (2011)
J Mol Cell Biol 3, 159-166
   Abstract »    Full Text »    PDF »
Pathogenesis of Non-Hodgkin's Lymphoma.
H. Nogai, B. Dorken, and G. Lenz (2011)
J. Clin. Oncol. 29, 1803-1811
   Abstract »    Full Text »    PDF »
Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas.
T. L. Naylor, H. Tang, B. A. Ratsch, A. Enns, A. Loo, L. Chen, P. Lenz, N. J. Waters, W. Schuler, B. Dorken, et al. (2011)
Cancer Res. 71, 2643-2653
   Abstract »    Full Text »    PDF »
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma.
B. Burington, P. Yue, X. Shi, R. Advani, J. T. Lau, J. Tan, S. Stinson, J. Stinson, T. Januario, S. de Vos, et al. (2011)
Science Translational Medicine 3, 74ra22
   Abstract »    Full Text »    PDF »
CARMA3 is Crucial for EGFR-Induced Activation of NF-{kappa}B and Tumor Progression.
T. Jiang, B. Grabiner, Y. Zhu, C. Jiang, H. Li, Y. You, J. Lang, M.-C. Hung, and X. Lin (2011)
Cancer Res. 71, 2183-2192
   Abstract »    Full Text »    PDF »
A20, ABIN-1/2, and CARD11 Mutations and Their Prognostic Value in Gastrointestinal Diffuse Large B-Cell Lymphoma.
G. Dong, E. Chanudet, N. Zeng, A. Appert, Y.-W. Chen, W.-Y. Au, R. A. Hamoudi, A. J. Watkins, H. Ye, H. Liu, et al. (2011)
Clin. Cancer Res. 17, 1440-1451
   Abstract »    Full Text »    PDF »
NF-{kappa}B Down-regulates Expression of the B-lymphoma Marker CD10 through a miR-155/PU.1 Pathway.
R. C. Thompson, M. Herscovitch, I. Zhao, T. J. Ford, and T. D. Gilmore (2011)
J. Biol. Chem. 286, 1675-1682
   Abstract »    Full Text »    PDF »
CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation.
L. E. Tze, K. Horikawa, H. Domaschenz, D. R. Howard, C. M. Roots, R. J. Rigby, D. A. Way, M. Ohmura-Hoshino, S. Ishido, C. E. Andoniou, et al. (2011)
J. Exp. Med. 208, 149-165
   Abstract »    Full Text »    PDF »
Local microbleeding facilitates IL-6- and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells.
M. Murakami, Y. Okuyama, H. Ogura, S. Asano, Y. Arima, M. Tsuruoka, M. Harada, M. Kanamoto, Y. Sawa, Y. Iwakura, et al. (2011)
J. Exp. Med. 208, 103-114
   Abstract »    Full Text »    PDF »
Critical role of PI3K signaling for NF-{kappa}B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
B. Kloo, D. Nagel, M. Pfeifer, M. Grau, M. Duwel, M. Vincendeau, B. Dorken, P. Lenz, G. Lenz, and D. Krappmann (2011)
PNAS 108, 272-277
   Abstract »    Full Text »    PDF »
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
G. Ott, M. Ziepert, W. Klapper, H. Horn, M. Szczepanowski, H.-W. Bernd, C. Thorns, A. C. Feller, D. Lenze, M. Hummel, et al. (2010)
Blood 116, 4916-4925
   Abstract »    Full Text »    PDF »
Host Factors for Risk and Survival in Lymphoma.
S. S. Dave (2010)
Hematology 2010, 255-258
   Abstract »    Full Text »    PDF »
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.
J. M. Hildebrand, Z. Luo, M. K. Manske, T. Price-Troska, S. C. Ziesmer, W. Lin, B. S. Hostager, S. L. Slager, T. E. Witzig, S. M. Ansell, et al. (2010)
J. Exp. Med. 207, 2569-2579
   Abstract »    Full Text »    PDF »
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
M. A. Milhollen, T. Traore, J. Adams-Duffy, M. P. Thomas, A. J. Berger, L. Dang, L. R. Dick, J. J. Garnsey, E. Koenig, S. P. Langston, et al. (2010)
Blood 116, 1515-1523
   Abstract »    Full Text »    PDF »
The CARMA3-Bcl10-MALT1 Signalosome Promotes Angiotensin II-dependent Vascular Inflammation and Atherogenesis.
L. M. McAllister-Lucas, X. Jin, S. Gu, K. Siu, S. McDonnell, J. Ruland, P. C. Delekta, M. Van Beek, and P. C. Lucas (2010)
J. Biol. Chem. 285, 25880-25884
   Abstract »    Full Text »    PDF »
Interplay between BCL10, MALT1 and I{kappa}B{alpha} during T-cell-receptor-mediated NF{kappa}B activation.
G. Carvalho, A. Le Guelte, C. Demian, A. Vazquez, J. Gavard, and N. Bidere (2010)
J. Cell Sci. 123, 2375-2380
   Abstract »    Full Text »    PDF »
Role of Molecular Subtype in Predicting Outcome of AIDS-Related Diffuse Large B-Cell Lymphoma.
K. Dunleavy and W. H. Wilson (2010)
J. Clin. Oncol. 28, e260
   Full Text »    PDF »
Oncogenic Activation of NF-{kappa}B.
L. M. Staudt (2010)
Cold Spring Harb Perspect Biol 2, a000109
   Abstract »    Full Text »    PDF »
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
K. Dunleavy, R. F. Little, S. Pittaluga, N. Grant, A. S. Wayne, J. A. Carrasquillo, S. M. Steinberg, R. Yarchoan, E. S. Jaffe, and W. H. Wilson (2010)
Blood 115, 3017-3024
   Abstract »    Full Text »    PDF »
Genomic Analysis of Lymphoma: Potential for Clinical Application.
W. C. Chan and J. O. Armitage (2010)
J Natl Compr Canc Netw 8, 353-360
   Abstract »    Full Text »    PDF »
MAGUK-Controlled Ubiquitination of CARMA1 Modulates Lymphocyte NF-{kappa}B Activity.
M. E. Moreno-Garcia, K. Sommer, H. Shinohara, A. D. Bandaranayake, T. Kurosaki, and D. J. Rawlings (2010)
Mol. Cell. Biol. 30, 922-934
   Abstract »    Full Text »    PDF »
Serine 649 Phosphorylation within the Protein Kinase C-Regulated Domain Down-Regulates CARMA1 Activity in Lymphocytes.
M. E. Moreno-Garcia, K. Sommer, C. Haftmann, C. Sontheimer, S. F. Andrews, and D. J. Rawlings (2009)
J. Immunol. 183, 7362-7370
   Abstract »    Full Text »    PDF »
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
S. Hailfinger, G. Lenz, V. Ngo, A. Posvitz-Fejfar, F. Rebeaud, M. Guzzardi, E.-M. M. Penas, J. Dierlamm, W. C. Chan, L. M. Staudt, et al. (2009)
PNAS 106, 19946-19951
   Abstract »    Full Text »    PDF »
NF-{kappa}B as a Critical Link Between Inflammation and Cancer.
M. Karin (2009)
Cold Spring Harb Perspect Biol 1, a000141
   Abstract »    Full Text »    PDF »
Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
U. Ferch, B. Kloo, A. Gewies, V. Pfander, M. Duwel, C. Peschel, D. Krappmann, and J. Ruland (2009)
J. Exp. Med. 206, 2313-2320
   Abstract »    Full Text »    PDF »
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.
K. Honma, S. Tsuzuki, M. Nakagawa, H. Tagawa, S. Nakamura, Y. Morishima, and M. Seto (2009)
Blood 114, 2467-2475
   Abstract »    Full Text »    PDF »
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
K. Dunleavy, S. Pittaluga, M. S. Czuczman, S. S. Dave, G. Wright, N. Grant, M. Shovlin, E. S. Jaffe, J. E. Janik, L. M. Staudt, et al. (2009)
Blood 113, 6069-6076
   Abstract »    Full Text »    PDF »
IRF4: Immunity. Malignancy! Therapy?.
A. L. Shaffer, N.C. T. Emre, P. B. Romesser, and L. M. Staudt (2009)
Clin. Cancer Res. 15, 2954-2961
   Abstract »    Full Text »    PDF »
Compensatory IKK{alpha} activation of classical NF-{kappa}B signaling during IKK{beta} inhibition identified by an RNA interference sensitization screen.
L. T. Lam, R. E. Davis, V. N. Ngo, G. Lenz, G. Wright, W. Xu, H. Zhao, X. Yu, L. Dang, and L. M. Staudt (2008)
PNAS 105, 20798-20803
   Abstract »    Full Text »    PDF »
The Protein Kinase C-Responsive Inhibitory Domain of CARD11 Functions in NF-{kappa}B Activation To Regulate the Association of Multiple Signaling Cofactors That Differentially Depend on Bcl10 and MALT1 for Association.
R. R. McCully and J. L. Pomerantz (2008)
Mol. Cell. Biol. 28, 5668-5686
   Abstract »    Full Text »    PDF »
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
G. Lenz, G. W. Wright, N. C. T. Emre, H. Kohlhammer, S. S. Dave, R. E. Davis, S. Carty, L. T. Lam, A. L. Shaffer, W. Xiao, et al. (2008)
PNAS 105, 13520-13525
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882